𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
𝗝&𝗝 𝗮𝗻𝗱 𝗟𝗲𝗴𝗲𝗻𝗱 𝘀𝗮𝘆 𝗖𝗮𝗿𝘃𝘆𝗸𝘁𝗶 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗶𝗻 𝗲𝗮𝗿𝗹𝗶𝗲𝗿-𝗹𝗶𝗻𝗲 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 In a late-stage study, Johnson & Johnson and Legend Biotech CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three … https://lnkd.in/dfUE5XyR
-
Luminary Group reposted this
𝐄𝐮𝐫𝐨 𝐓𝐡𝐞𝐦𝐞𝐝 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐈𝐧𝐜𝐞𝐧𝐭𝐢𝐯𝐞 𝐃𝐚𝐲 ⚽ We organize a company-wide incentive day 3 to 4 times a year, where all our offices and sister companies get together. This time, we embraced a Euro theme and divided into teams representing Germany, Italy, and England. Throughout the day everyone was involved in various activities to gain points and prizes. The highlights of the day were our penalty shootouts and the refs handing out yellow and red cards 😂 Congratulations to the team representing Germany for claiming victory! 🏆 Like always, it was a day filled with laughter, motivation, and lots of success. Thank you to Luminary Group for joining us and everyone in the team for your effort and high spirits! Looking forward to the next incentive day!
-
𝗗𝘂𝗽𝗶𝘅𝗲𝗻𝘁 𝘄𝗶𝗻𝘀 𝗘𝗨 𝗹𝗮𝗯𝗲𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗶𝗻 𝗖𝗢𝗣𝗗 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝗱𝗲𝗹𝗮𝘆𝗲𝗱 𝗙𝗗𝗔 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 Sanofi and Regeneron Therapeutics INC DUPIXENT® (dupilumab) HCP has notched another indication in the EU, this time for a common lung disease, marking the first-ever targeted therapy for the … https://lnkd.in/dsuPtPe2
Sanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA
https://endpts.com
-
𝗕𝗶𝗼𝗴𝗲𝗻 𝗶𝘀 𝗽𝘂𝗿𝘀𝘂𝗶𝗻𝗴 𝗺𝗼𝗿𝗲 𝗱𝗲𝗮𝗹𝗺𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝘆𝗲𝗮𝗿, 𝘄𝗶𝘁𝗵 𝗽𝗹𝗮𝗻𝘀 𝘁𝗼 𝘀𝗽𝗲𝗻𝗱 𝘂𝗽 𝘁𝗼 $𝟴𝗕 Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated. Adam Keeney PhD https://lnkd.in/dim-XMyW
Biogen is pursuing more dealmaking this year, with plans to spend up to $8B
https://endpts.com
-
𝗠𝗼𝗱𝗲𝗿𝗻𝗮 𝘄𝗶𝗻𝘀 $𝟭𝟳𝟲𝗠 𝗕𝗔𝗥𝗗𝗔 𝗮𝘄𝗮𝗿𝗱 𝘁𝗼 𝗳𝗶𝗻𝗮𝗻𝗰𝗲 𝗯𝗶𝗿𝗱 𝗳𝗹𝘂 𝘄𝗼𝗿𝗸 Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was … https://lnkd.in/ddasMenm
Moderna wins $176M BARDA award to finance bird flu work
https://endpts.com
-
𝗜𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵'𝘀 𝘂𝗻𝗲𝘃𝗲𝗻 𝗿𝗲𝗰𝗼𝘃𝗲𝗿𝘆, 𝟱𝟬 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗿𝗮𝗶𝘀𝗲𝗱 𝗺𝗲𝗴𝗮𝗿𝗼𝘂𝗻𝗱𝘀 𝗶𝗻 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟰 The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens If that pace continues, it … https://lnkd.in/dvVXbFfg
In biotech’s uneven recovery, 50 startups raised megarounds in first half of 2024
https://endpts.com
-
𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝘄𝗶𝗻𝘀 𝗹𝗼𝗻𝗴-𝗮𝘄𝗮𝗶𝘁𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗿𝘂𝗴 After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly and Company has finally won FDAQRC approval for its drug donanemab …Dave Ricks https://lnkd.in/ew3w8MdM
Eli Lilly wins long-awaited approval for Alzheimer’s drug
https://endpts.com
-
Happy 4th of July from the team at Luminary Group! Wishing our clients and candidates across the United States a joyful and safe celebration. Thank you for being a part of our community! #independenceday #4thofjuly #usaindependenceday 🇺🇸
-
𝗕𝗲𝗮𝗰𝗼𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟳𝟬𝗠 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗼𝗻 𝗝&𝗝 𝗶𝗻 𝗼𝗰𝘂𝗹𝗮𝗿 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson …David Fellows https://lnkd.in/dyS8QmmW
Beacon raises $170M to take on J&J in ocular gene therapy
https://endpts.com